Key facts
- Exo’s last known valuation is $645.0M (Apr 2021).
- It has raised $409.4M; the latest was Debt - General ($7.5M) in Dec 2025.
- Notable investors include RA Capital Management, Samsung Venture Investment, Intel Capital, Sony Innovation Fund, Page One Ventures — 37 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 37 names
- ·Watchlist + deal alerts for Exo
- ·The full record, as it builds
Funding rounds
No funding rounds for Exo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Exo
Developer of a handheld ultrasound device designed for medical imaging and therapeutic applications. The company's technology combines advanced nano-materials, novel sensor technologies, advanced signal processing, and computation with the economies of scale of semiconductor manufacturing, enabling healthcare professionals to make critical, real-time decisions that improve patient outcomes at a lower and more convenient cost.
- Sector
- Healthcare
- HQ
- Santa Clara, CA, United States
- Founded
- 2015
- Employees
- 187
- Website
- exo.inc/
- Ownership
- Privately Held (backing)
Exo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Exo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Exo in its N-PORT filings yet. We sweep new filings monthly.